Dr. Martin was a graduate scholar in the NIH Comparative Biomedical Scientist Training Program in partnership with University of Maryland and the National Cancer Institute, 2005 – 2014.
Dr. Martin received his B.S. from Northwestern University, his M.S. from Ohio University and his D.V.M. from Kansas State University in 2003. After completing the D.V.M. Dr. Martin went to the University of California, Davis for residency training in anatomic pathology in the Department of Veterinary Pathology. As an anatomic pathology resident Dr. Martin pursued specialty track training in the pathology of laboratory animals and undertook training in the UC Davis Comparative Pathology Laboratory and the Pathology Department of the California Regional Primate Center. In 2005 Dr. Martin began training in comparative pathology through the Graduate Partnership Program at the National Cancer Institute, Bethesda MD. The first year of the GPP program was spent completing graduate course work at the University of Maryland and in additional anatomic pathology training while working in the Comparative Molecular Pathology Unit with Dr. Mark Simpson. Dr. Martin accomplished board certification in Anatomic Pathology by The American College of Veterinary Pathologists in 2006. Dr. Martin is carried out his dissertation research in the NCI Laboratory of Genitourinary Cancer Pathogenesis, headed by Kathy Kelly, PhD. His Ph.D. dissertation research involved developing an in-vivo bioluminescent transgenic mouse model of prostate cancer metastasis for the purpose of investigating the molecular signaling mechanisms responsible for driving prostate cancer metastasis. Members of his graduate guidance committee included Siba Samal, B.V.Sc., Ph.D., Diplomate, The American College of Veterinary Microbiologists (chair), Xiaoping Zhu, D.V.M., Ph.D., Robert Dooling, Ph.D., Kathy Kelly, Ph.D., and Mark Simpson, D.V.M., Ph.D, Diplomate, The American College of Veterinary Pathologists. Upon receiving his Ph.D., Dr. Martin worked as a veterinary pathologist for the NCI Frederick’s Center for Advanced Preclinical Research. He currently is employed by MedImmune/AstraZeneca.
